LAG3+ CD8+ T cell Subset Drives HR+/HER2− Breast Cancer Reduction in Bispecific Antibody Armed Activated T Cell Therapy
Preprint
Abstract
Tumor clearance by T cells is impaired by insufficient tumor antigen recognition, insufficient tumor infiltration, and the immunosuppressive tumor microenvironment (TME). Although targeted T cell therapy circumvents failures in tumor antigen recognition, suppression by the TME and failure to infiltrate the tumor can hinder tumor clearance. Checkpoint inhibitors (CPI) promise to reverse T cell suppression and can be combined with bispecific antibody armed T cell (BATs) therapy to improve clinical outcomes. We hypothesize that adoptively transferred T cell function may be improved by the addition of CPI if the inhibitory pathway is functionally active. This study develops a kinetic-dynamic model of killing of hormone receptor-positive (HR+) breast cancer cells mediated by BATs using single-cell transcriptomic and temporal protein data to identify T cell phenotypes and quantify inhibitory receptor expression. LAG3, PD-1, and TIGIT were identified as inhibitory receptors expressed by cytotoxic effector CD8 BATs upon exposure to HR+ breast cancer cell lines. These data were combined with real-time tumor cytotoxicity data in a multivariate statistical analysis framework to predict the relevant contributions of T cells expressing each receptor to tumor reduction. A mechanistic kinetic-dynamic mathematical model was developed and parametrized using protein expression and cytotoxicity data for in silico validation of the findings of the multivariate statistical analysis. The model corroborated the predictions of the multivariate statistical analysis which identified LAG3+ BATs as the primary effectors, while TIGIT expression dampened cytotoxic function. These results inform CPI selection for BATs combination therapy and provide a framework to maximize BATs anti-tumor function. What is already known on this topic Bispecific antibody armed T cell (BATs) therapies are adoptive T cell therapies that can effectively reroute T cell cytotoxicity toward cancerous cells, but lack consistent and durable anti-tumor responses. Checkpoint proteins expressed on the surface of activated T cells dampen immune responses and can be overstimulated in solid tumors to hamper tumor clearance by T cells. Checkpoint inhibitor drugs can improve T cell anti-tumor response by blocking checkpoint protein signaling but are only effective if the targeted checkpoint protein is expressed on the T cell and activated in the tumor microenvironment, highlighting an opportunity to enhance BAT efficacy by combining treatment with synergistic CPI. What this study adds This study characterizes dynamic, time-resolved patterns in checkpoint protein expression by breast cancer-targeting adoptive T cells and predicts the significance of high-prevalence checkpoint proteins on T cell function. It also demonstrates the use of multivariate statistic and mathematical modeling toward rational design of targets and timing strategies for synergistic combination therapies. How this study might affect research, practice, or policy The output of this study provides justification for therapeutic strategies combining adoptive T cell therapies with checkpoint inhibitor drugs targeting TIGIT and LAG3 as a means of improving patient responses in HER2−/HR+ breast cancers.Keywords
All Related Versions
- Published version: The Journal of Immunology, 214 (10), 2756.
Funding Information
- UVA Cancer Center Support Grant P30 (CA044579)
This publication has 79 references indexed in Scilit:
- LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunityCell, 2024
- LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicityCell, 2024
- Our current understanding of checkpoint inhibitor therapy in cancer immunotherapyAnnals of Allergy, Asthma & Immunology, 2021
- Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor studyBreast Cancer Research and Treatment, 2017
- Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancerCurrent Opinion in Immunology, 2017
- A Dynamic Model of Immune Responses to Antigen Presentation Predicts Different Regions of Tumor or Pathogen EliminationCell Systems, 2017
- CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's LymphomaTransplantation and Cellular Therapy, 2013
- Performance of some variable selection methods when multicollinearity is presentChemometrics and Intelligent Laboratory Systems, 2005
- The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cellsEuropean Journal of Immunology, 2003
- Preclinical Studies Using Immobilized OKT3 to Activate Human T Cells for Adoptive Immunotherapy: Optimal Conditions for the Proliferation and Induction of Non-MHC-Restricted CytotoxicityClinical Immunology and Immunopathology, 1994